Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening...

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Anti-cancer drug efficacy is linked to tumor cell proliferation.
• Existing knowledge of cancer drug cell cycle specificities lacks quantitative description.
• Understanding cell cycle-dependent drug action is crucial for effective cancer treatment.

Purpose of the Study:

• To develop a quantitative method for assessing cell cycle specificity of anti-cancer drugs.
• To establish a scalable protocol for screening drug libraries based on cell cycle phase.
• To identify novel drug scheduling strategies for enhanced anti-cancer efficacy.

Main Methods:

• A scalable cell synchronization protocol was employed.
• A library of 235 anti-cancer compounds was screened.
• Compounds were tested on AsPC-1 cells synchronized in G1 or S/G2 phases over six hours.
• A cell cycle specificity (CCS) score was generated for each compound.

Main Results:

• The synchronization method demonstrated reduced cytotoxicity compared to nocodazole.
• High cell cycle purity and sufficient cell numbers were achieved for high-throughput screening.
• Compounds with G1 and S/G2-associated specificities were identified, correlating with their known targets.
• A synergistic drug schedule involving palbociclib, gemcitabine, and AZD6738 was proposed.
• Correlation between CCS scores and published drug synergy data was established.

Conclusions:

• A novel, quantitative method for describing cell cycle-dependent drug sensitivities was developed.
• The method is scalable, tractable, and well-tolerated, with potential applications beyond this study.
• Findings suggest that drug scheduling, particularly for G1 or S/G2-associated agents, can be optimized.
• Specific scheduling considerations, such as using CDK4/6 inhibitors prior to other agents, may improve therapeutic outcomes.